Table 1. Principal studies including MPN... | American Society of Hematology

Table 1.

Principal studies including MPN patients on VKA treatment for usual site VTE

Reference	Study population	N included in the study	N on VKAs	Overall thrombosis recurrence (A/V)	VTE recurrence	Major bleeding	Median follow-up (years)
De Stefano et al¹⁴	PV/ET with at least 1 episode of thrombosis (ATE and VTE)	494	90	33.6% (7.6% pt-y)^*	13.1% (3% pt-y)^*	5.4% (0.9% pt-y)^* 7.7% (0.9% pt-y)^† (2.8 pt-y)^‡	5.3
Hernandez-Boluda et al¹⁶	PV/ET receiving VKA for a first VTE or ATE episode	150	150	28% (6.0% pt-y)^†	24% (2.7% ON vs 9.0% OFF, p)^†	11.3% (overall 1.7% pt-y, 1.8% ON vs 1.5% OFF)^†	7.7
De Stefano et al¹⁵	PV/ET/PMF on systemic anticoagulation for a first VTE episode	206	155	21.8% (6.5% pt-y)^* 12.2% (4.7% pt-y)^†	17.4% (5.2% pt-y)^* 9.6% (4.2% pt-y ON vs 9.6% pt-y OFF)^†	6.4% (2.4% ON vs 0.7 OFF)^†	3
Wille et al¹⁷	PV/ET/PMF with a first VTE episode	78	40	—	20.5% (6.0% pt-y)^*	26.9%	2

Reference	Study population	N included in the study	N on VKAs	Overall thrombosis recurrence (A/V)	VTE recurrence	Major bleeding	Median follow-up (years)
De Stefano et al¹⁴	PV/ET with at least 1 episode of thrombosis (ATE and VTE)	494	90	33.6% (7.6% pt-y)^*	13.1% (3% pt-y)^*	5.4% (0.9% pt-y)^* 7.7% (0.9% pt-y)^† (2.8 pt-y)^‡	5.3
Hernandez-Boluda et al¹⁶	PV/ET receiving VKA for a first VTE or ATE episode	150	150	28% (6.0% pt-y)^†	24% (2.7% ON vs 9.0% OFF, p)^†	11.3% (overall 1.7% pt-y, 1.8% ON vs 1.5% OFF)^†	7.7
De Stefano et al¹⁵	PV/ET/PMF on systemic anticoagulation for a first VTE episode	206	155	21.8% (6.5% pt-y)^* 12.2% (4.7% pt-y)^†	17.4% (5.2% pt-y)^* 9.6% (4.2% pt-y ON vs 9.6% pt-y OFF)^†	6.4% (2.4% ON vs 0.7 OFF)^†	3
Wille et al¹⁷	PV/ET/PMF with a first VTE episode	78	40	—	20.5% (6.0% pt-y)^*	26.9%	2

^*

Entire cohort.

Patients on VKA only.

Patients on VKA and aspirin.

A/V, arterial/venous; N, number of patients; ON, on VKA; OFF, off VKA; Pt-y, patient-years.